Cargando…

Rapid obtention of stable, bioluminescent tumor cell lines using a tCD2-luciferase chimeric construct

BACKGROUND: Bioluminescent tumor cell lines are experimental tools of major importance for cancer investigation, especially imaging of tumors in xenografted animals. Stable expression of exogenous luciferase in tumor cells combined to systemic injection of luciferin provides an excellent signal/back...

Descripción completa

Detalles Bibliográficos
Autores principales: Jimenez, Anne-Sophie, Gressette, Mélanie, Barjon, Clément, Wei, Ming, Gourzones, Claire, Busson, Pierre
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3078863/
https://www.ncbi.nlm.nih.gov/pubmed/21435248
http://dx.doi.org/10.1186/1472-6750-11-26
_version_ 1782201976972378112
author Jimenez, Anne-Sophie
Gressette, Mélanie
Barjon, Clément
Wei, Ming
Gourzones, Claire
Busson, Pierre
author_facet Jimenez, Anne-Sophie
Gressette, Mélanie
Barjon, Clément
Wei, Ming
Gourzones, Claire
Busson, Pierre
author_sort Jimenez, Anne-Sophie
collection PubMed
description BACKGROUND: Bioluminescent tumor cell lines are experimental tools of major importance for cancer investigation, especially imaging of tumors in xenografted animals. Stable expression of exogenous luciferase in tumor cells combined to systemic injection of luciferin provides an excellent signal/background ratio for external optical imaging. Therefore, there is a need to rationalize and speed up the production of luciferase-positive tumor cell lines representative of multiple tumor phenotypes. For this aim we have designed a fusion gene linking the luciferase 2 protein to the c-terminus of a truncated form of the rat CD2 protein (tCD2-luc2). To allow simultaneous assessment of the wild-type luciferase 2 in a context of tCD2 co-expression, we have made a bicistronic construct for concomitant but separate expression of these two proteins (luc2-IRES-tCD2). Both the mono- and bi-cistronic constructs were transduced in lymphoid and epithelial cells using lentiviral vectors. RESULTS: The tCD2-luc2 chimera behaves as a type I membrane protein with surface presentation of CD2 epitopes. One of these epitopes reacts with the OX34, a widely spread, high affinity monoclonal antibody. Stably transfected cells are sorted by flow cytometry on the basis of OX34 staining. In vitro and, moreover, in xenografted tumors, the tCD2-luc2 chimera retains a substantial and stable luciferase activity, although not as high as the wild-type luciferase expressed from the luc2-IRES-tCD2 construct. Expression of the tCD2-luc2 chimera does not harm cell and tumor growth. CONCLUSION: Lentiviral transduction of the chimeric tCD2-luc2 fusion gene allows selection of cell clones with stable luciferase expression in less than seven days without antibiotic selection. We believe that it will be helpful to increase the number of tumor cell lines available for in vivo imaging and assessment of novel therapeutic modalities. On a longer term, the tCD2-luc2 chimera has the potential to be expressed from multi-cassette vectors in combination with various inserts of interest.
format Text
id pubmed-3078863
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30788632011-04-19 Rapid obtention of stable, bioluminescent tumor cell lines using a tCD2-luciferase chimeric construct Jimenez, Anne-Sophie Gressette, Mélanie Barjon, Clément Wei, Ming Gourzones, Claire Busson, Pierre BMC Biotechnol Methodology Article BACKGROUND: Bioluminescent tumor cell lines are experimental tools of major importance for cancer investigation, especially imaging of tumors in xenografted animals. Stable expression of exogenous luciferase in tumor cells combined to systemic injection of luciferin provides an excellent signal/background ratio for external optical imaging. Therefore, there is a need to rationalize and speed up the production of luciferase-positive tumor cell lines representative of multiple tumor phenotypes. For this aim we have designed a fusion gene linking the luciferase 2 protein to the c-terminus of a truncated form of the rat CD2 protein (tCD2-luc2). To allow simultaneous assessment of the wild-type luciferase 2 in a context of tCD2 co-expression, we have made a bicistronic construct for concomitant but separate expression of these two proteins (luc2-IRES-tCD2). Both the mono- and bi-cistronic constructs were transduced in lymphoid and epithelial cells using lentiviral vectors. RESULTS: The tCD2-luc2 chimera behaves as a type I membrane protein with surface presentation of CD2 epitopes. One of these epitopes reacts with the OX34, a widely spread, high affinity monoclonal antibody. Stably transfected cells are sorted by flow cytometry on the basis of OX34 staining. In vitro and, moreover, in xenografted tumors, the tCD2-luc2 chimera retains a substantial and stable luciferase activity, although not as high as the wild-type luciferase expressed from the luc2-IRES-tCD2 construct. Expression of the tCD2-luc2 chimera does not harm cell and tumor growth. CONCLUSION: Lentiviral transduction of the chimeric tCD2-luc2 fusion gene allows selection of cell clones with stable luciferase expression in less than seven days without antibiotic selection. We believe that it will be helpful to increase the number of tumor cell lines available for in vivo imaging and assessment of novel therapeutic modalities. On a longer term, the tCD2-luc2 chimera has the potential to be expressed from multi-cassette vectors in combination with various inserts of interest. BioMed Central 2011-03-24 /pmc/articles/PMC3078863/ /pubmed/21435248 http://dx.doi.org/10.1186/1472-6750-11-26 Text en Copyright ©2011 Jimenez et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Methodology Article
Jimenez, Anne-Sophie
Gressette, Mélanie
Barjon, Clément
Wei, Ming
Gourzones, Claire
Busson, Pierre
Rapid obtention of stable, bioluminescent tumor cell lines using a tCD2-luciferase chimeric construct
title Rapid obtention of stable, bioluminescent tumor cell lines using a tCD2-luciferase chimeric construct
title_full Rapid obtention of stable, bioluminescent tumor cell lines using a tCD2-luciferase chimeric construct
title_fullStr Rapid obtention of stable, bioluminescent tumor cell lines using a tCD2-luciferase chimeric construct
title_full_unstemmed Rapid obtention of stable, bioluminescent tumor cell lines using a tCD2-luciferase chimeric construct
title_short Rapid obtention of stable, bioluminescent tumor cell lines using a tCD2-luciferase chimeric construct
title_sort rapid obtention of stable, bioluminescent tumor cell lines using a tcd2-luciferase chimeric construct
topic Methodology Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3078863/
https://www.ncbi.nlm.nih.gov/pubmed/21435248
http://dx.doi.org/10.1186/1472-6750-11-26
work_keys_str_mv AT jimenezannesophie rapidobtentionofstablebioluminescenttumorcelllinesusingatcd2luciferasechimericconstruct
AT gressettemelanie rapidobtentionofstablebioluminescenttumorcelllinesusingatcd2luciferasechimericconstruct
AT barjonclement rapidobtentionofstablebioluminescenttumorcelllinesusingatcd2luciferasechimericconstruct
AT weiming rapidobtentionofstablebioluminescenttumorcelllinesusingatcd2luciferasechimericconstruct
AT gourzonesclaire rapidobtentionofstablebioluminescenttumorcelllinesusingatcd2luciferasechimericconstruct
AT bussonpierre rapidobtentionofstablebioluminescenttumorcelllinesusingatcd2luciferasechimericconstruct